LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA..

宾夕法尼亚州兰格霍恩市（商业新闻短讯）--萨瓦拉公司（Nasdaq:SVRA）（该公司）是一家专注于罕见呼吸道疾病的临床阶段生物制药公司，今天宣布接受两份摘要，以在2024年5月17日至22日于加利福尼亚州圣地亚哥举行的美国胸科学会（ATS）2024年国际会议上进行海报展示。。

“We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP,” said Matt Pauls, Chair and CEO, Savara. “We are also keen to increase awareness and understanding of this rare and chronic lung disease through our Industry Theater with two aPAP experts.”.

萨瓦拉主席兼首席执行官马特·保尔斯（Matt Pauls）表示：“我们期待着在ATS上看到有关aPAP患者面临的重大医疗负担、诊断挑战以及基于实验室的新型自身抗体血液检测的发展的数据，该检测可以提供aPAP的明确诊断。”。“我们还希望通过与两位aPAP专家合作的行业剧场，提高对这种罕见和慢性肺病的认识和理解。”。

ATS 2024 Accepted Abstracts:

ATS 2024接受摘要：

Savara

绍沃劳

701: Healthcare Burden of Pulmonary Alveolar Proteinosis

701：肺泡蛋白沉着症的医疗负担

Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant

海报会议A26：改善结节病，罕见肺病和肺移植的结果

Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT

海报讨论会：2024年5月19日，星期日，太平洋夏令时上午9:15-11:15

Trillium Health

延龄草健康

702: Development of a Novel Laboratory Test for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Individuals At-Risk for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

702：开发一种检测GM-CSF抗体的新型实验室检测方法，以帮助诊断有自身免疫性肺泡蛋白沉着症（aPAP）风险的个体

Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant

海报会议A26：改善结节病，罕见肺病和肺移植的结果

Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT

海报讨论会：2024年5月19日，星期日，太平洋夏令时上午9:15-11:15

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024. For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php.

这些摘要将于2024年5月1日发表在《美国呼吸与重症监护医学杂志》（AJRCCM）的增刊上。有关ATS国际会议的更多详细信息，请访问https://conference.thoracic.org/index.php.

Industry Theater:

工业剧院：

Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management

肺泡蛋白沉积症（PAP）：病理生理学，诊断和管理

Sunday, May 19, 2024, 1:15-2:00 PM PDT

2024年5月19日星期日，太平洋夏令时下午1:15-2:00

Bruce Trapnell, M.D., M.S. and Tisha Wang, M.D. will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

Bruce Trapnell，M.D.，M.S.和Tisha Wang，M.D.将提供PAP的概述，包括这种罕见肺部疾病的负担，自身免疫性PAP（aPAP）的标志性体征和症状，最常见的PAP形式，以及诊断aPAP的途径。

About aPAP

关于aPAP

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP). aPAP represents about 90% of all patients with PAP. While aPAP can affect people of any age, race or sex, onset occurs most frequently in people between the ages of 30 and 40.

自身免疫性肺泡蛋白沉着症（aPAP）是一种罕见的肺部疾病，属于一种独特的罕见肺部疾病家族，统称为肺泡蛋白沉着症（PAP）。aPAP约占所有PAP患者的90%。虽然aPAP可以影响任何年龄，种族或性别的人，但发病最常见于30至40岁之间的人。

PAP is characterized by the build-up of surfactant in the alveoli, or air sacs, of the lungs. The surfactant consists of proteins and lipids and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. The root cause of aPAP is an autoimmune response against GM-CSF, a naturally occurring protein in the body.

PAP的特征是肺泡或气囊中表面活性剂的积累。表面活性剂由蛋白质和脂质组成，是一种重要的生理物质，排列在肺泡内部，以防止肺部塌陷。aPAP的根本原因是针对GM-CSF的自身免疫反应，GM-CSF是体内天然存在的蛋白质。

Pulmonary macrophages need to be stimulated by GM-CSF to function properly, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering the macrophages unable to perform their tasks, including the clearance of surfactant from the alveoli. In aPAP, the feeling of having trouble breathing is the most common symptom.

肺巨噬细胞需要GM-CSF刺激才能正常工作，但在aPAP中，GM-CSF被抗GM-CSF的抗体中和，使巨噬细胞无法执行其任务，包括从肺泡清除表面活性剂。在aPAP中，呼吸困难的感觉是最常见的症状。

People with aPAP can also experience chronic cough, fatigue, sputum production, reduced ability to exercise and episodes of fever due to underlying pulmonary infections..

aPAP患者还可能经历慢性咳嗽，疲劳，痰液产生，运动能力下降以及由于潜在的肺部感染引起的发烧发作。。

About Savara

关于萨瓦拉

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH).

Savara是一家临床阶段的生物制药公司，专注于罕见的呼吸道疾病。我们的主要项目molgramostim雾化器溶液是一种吸入性粒细胞巨噬细胞集落刺激因子（GM-CSF），处于自身免疫性肺泡蛋白沉着症（aPAP）的3期发展中。Molgramostim通过研究性eFlow®雾化器系统（PARI Pharma GmbH）提供。

Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)..

我们的管理团队在罕见呼吸系统疾病和肺部医学方面拥有丰富的经验，能够识别未满足的需求，并有效地推动候选产品获得批准和商业化。更多信息可以在www.savarapharma.com上找到。（X，以前称为推特：@savarapharma，LinkedIn:www.LinkedIn.com/company/savara pharmaceuticals/）。。

Forward-Looking Statements

前瞻性声明

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others.

萨瓦拉提醒您，本新闻稿中的声明并非对历史事实的描述，而是1995年《私人证券诉讼改革法案》所指的前瞻性声明。前瞻性陈述可以通过使用引用未来事件或情况的词语来识别，例如“预期”、“打算”、“计划”、“预期”、“相信”和“将会”等。

Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.

萨瓦拉可能无法实际实现此类前瞻性声明中提及的任何事项，您不应过度依赖这些前瞻性声明。这些前瞻性陈述基于萨瓦拉目前的预期，并涉及可能永远不会实现或可能被证明不正确的假设。

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the outcome of our ongoing and planned clinical trials for our product candidate, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the ability to successfully develop our product candidate, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as molgramostim that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations.

由于各种风险和不确定性，实际结果和事件发生的时间可能与此类前瞻性声明中的预期有很大不同，这些风险和不确定性包括但不限于我们正在进行和计划中的候选产品临床试验的结果，预测未来现金利用率和或有未来负债和业务运营所需储备的能力，萨瓦拉运营所需的足够资源的可用性以及进行或继续计划的临床开发计划的能力，成功开发我们的候选产品的能力，与开发过程相关的风险，获得监管部门的批准和商业化候选药物，如安全有效地用作人类治疗药物的molgramostim，以及萨瓦拉根据需要筹集额外资本以资助持续的时间和能力操作。

All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and.

所有前瞻性陈述均由这些警示性陈述明确限定。详细描述我们的风险和。